Literature DB >> 12000384

In vitro/in vivo correlations between transdermal delivery of 5-aminolaevulinic acid and cutaneous protoporphyrin IX accumulation and effect of formulation.

J-C Tsai1, I-H Chen, T-W Wong, Y-L Lo.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) using topical application of 5-aminolaevulinic acid (ALA) has been widely reported for the treatment of a variety of neoplastic and non-neoplastic cutaneous diseases. Although different formulations containing variable amounts of ALA have been applied in PDT, the dose-response relationships between transdermal ALA delivery and cutaneous protoporphyrin IX (PpIX) accumulation have not been studied. OBJECTIVES AND METHODS: The objectives of this study were to investigate the effect of permeability barrier function, ALA concentration and formulation on the in vitro penetration of ALA through nude mouse skin and cutaneous PpIX formation at 2 h following a 2-h application of ALA to nude mouse skin in vivo, and to delineate the relationships in between.
RESULTS: Results demonstrated that variations in barrier integrity, in addition to ALA concentration, profoundly influenced ALA delivery to generate PpIX. Saturable correlations were found to exist between PpIX concentrations in both the epidermis and dermis in vivo and its transdermal flux in vitro, and the relationships were well described by the Emax model. The established correlations based on pure aqueous solutions were applicable to different formulations containing hydroxypropylmethylcellulose as the gelling agent and ethylenediamine tetraacetic acid as the iron chelator. Moreover, incorporation of desferrioxamine, another iron chelator, in the formulation prolonged cutaneous PpIX accumulation in the skin in comparison with 3% ALA aqueous solution, but the peak PpIX levels were not increased. Application of a liposomal formulation resulted in similar prolongation in ALA-induced PpIX accumulation, as well as better epidermal targeting.
CONCLUSIONS: Knowledge of the dose-response relationships and the effect of formulation is important for designing optimal formulations and treatment schedules for topical ALA-PDT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000384     DOI: 10.1046/j.1365-2133.2002.04715.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Comparative analysis of the effects of CO2 fractional laser and sonophoresis on human skin penetration with 5-aminolevulinic acid.

Authors:  J H Choi; E J Shin; K H Jeong; M K Shin
Journal:  Lasers Med Sci       Date:  2017-08-19       Impact factor: 3.161

2.  Autoradiographic and scintillation analysis of 5-aminolevulinic acid permeation through epithelialised tissue: implications for topical photodynamic therapy of superficial gynaecological neoplasias.

Authors:  Paul A McCarron; Ryan F Donnelly; A David Woolfson
Journal:  Pharm Res       Date:  2007-07-27       Impact factor: 4.200

3.  Fractional radiofrequency combined with sonophoresis to facilitate skin penetration of 5-aminolevulinic acid.

Authors:  Jong Min Park; Ki-Heon Jeong; Myong Il Bae; Sang-Jun Lee; Nack-In Kim; Min Kyung Shin
Journal:  Lasers Med Sci       Date:  2015-11-12       Impact factor: 3.161

4.  Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions.

Authors:  Li-Wen Zhang; Saleh A Al-Suwayeh; Chi-Feng Hung; Chih-Chieh Chen; Jia-You Fang
Journal:  Int J Nanomedicine       Date:  2011-04-05

5.  Update in the treatment of cutaneous leishmaniasis.

Authors:  Sahar H Al-Natour
Journal:  J Family Community Med       Date:  2009-05

Review 6.  Daylight Photodynamic Therapy: An Update.

Authors:  Chaw-Ning Lee; Rosie Hsu; Hsuan Chen; Tak-Wah Wong
Journal:  Molecules       Date:  2020-11-08       Impact factor: 4.411

7.  Derivatives of 5-aminolevulinic Acid for photodynamic therapy.

Authors:  Ryan F Donnelly; Paul A McCarron; A David Woolfson
Journal:  Perspect Medicin Chem       Date:  2007-12-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.